antibody

Vascular Endothelial Growth Factor (VEGF)

MBS340507

1 mL

465 USD

polyclonal

sheep

nonconjugated

western blot, ELISA, immunohistochemistry, enzyme immunoassay

Antibody

Vascular Endothelial Growth Factor (VEGF)

Vascular Endothelial Growth Factor (VEGF)

Vascular endothelial growth factor A; VEGF-A; Vascular permeability factor; VPF; VEGFA; VEGF

vascular endothelial growth factor; Vascular endothelial growth factor A; vascular endothelial growth factor A; vascular endothelial growth factor A; Vascular permeability factor; VPF

VEGF

VEGFA; VEGFA; VPF; VEGF; MVCD1; VEGF; VEGF-A; VPF

VEGFA_HUMAN

Polyclonal

Sheep

191

Ig Fraction - Liquid

>5mg/ml (U.V.abs @ 280nm)

Upon delivery aliquot and store at -20 degree C. Avoid freeze / thaw cycles. Short term storage 2 - 8 degree C.

ELISA (EIA), Western Blot (WB), Dot Blot (DB), Immunohistochemistry (IHC), Immunoassays, Development of Rapid tests and Other Immunoassay, Antibody Recognition Assays

Immunogen: Recombinant Human VEGF

Buffer: 20mM Phosphate, 150mM Sodium Chloride. Preservative: 0.09% Sodium Azide

Polyclonal Antibodies; Biochemical Markers; Proteins; Vascular Endothelial Growth Factor

VEGF is a heparin-binding glycoprotein, which can exist in a number of different isoforms. The protein has been found to be a potent inducer of angiogeneis and endothelial cell proliferation and plays an important role in regulating vasculogenesis. VEGF can be detected in both the plasma and serum and has been implicated in several disease states associated with augmented angiogenesis. Recombinant VEGF (165) comprises a 165 amino acid fragment (5-169) corresponding to the VEGF 165 isoform and is expressed in E Coli with an aminoterminal hexahistidine tag. This product is for research use only and is not intended for diagnostic or therapeutic use.

Ferrara, N. (1999) Curr. Top. Microbial. Immunol. 237: 1- 30. Banks, R.E. (1998) Br. J. Cancer 77 (6): 956-964.

181971

AAA35789.1

P15692

34,406 Da

AGE-RAGE Signaling Pathway In Diabetic Complications (1319988); AGE-RAGE Signaling Pathway In Diabetic Complications (1319775); Angiogenesis Pathway (198772); Axon Guidance Pathway (1270303); Bladder Cancer Pathway (83115); Bladder Cancer Pathway (527); Cellular Response To Hypoxia Pathway (1270415); Cellular Responses To Stress Pathway (1270414); Cytokine-cytokine Receptor Interaction Pathway (83051); Cytokine-cytokine Receptor Interaction Pathway (460)

This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site. [provided by RefSeq, Nov 2015]

1 mL

465 USD